Skip to main content
Journal cover image

Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients.

Publication ,  Journal Article
Bushnell, CD; Goldstein, LB
Published in: J Stroke Cerebrovasc Dis
2005

Observational study data have suggested that neurologists preferentially selected younger patients with generally few traditional stroke risk factors for homocysteine testing. The aim of this study was to corroborate observational data by assessing neurologists' reported practices for the detection and treatment of hyperhomocysteinemia in patients with acute ischemic stroke. All academic neurology faculty (n = 49), trainees (neurology residents/fellows, n = 53), and a random sample of community-based neurologists (n = 66) throughout North Carolina were surveyed regarding their homocysteine testing and treatment practices. Nine neurologists were ineligible because they had either retired or moved out of state. A total of 93 of the remaining 159 surveys (58.5%) were completed (response rates: faculty, 74%; trainees, 47%; community-based neurologists, 56%). Patients age < 50 years (n = 52; 63%) and the absence of traditional stroke risk factors (n = 57; 70%) were the most common factors cited as prompting homocysteine testing. The homocysteine level threshold for treatment varied independently by practice type (faculty: median, 14 mumol/L; range, 6-16 mumol/L; trainees: median, 14.5 mumol/L; range, 10-20 mumol/L; community-based: median, 10.4 mumol/L; range, 7-15 mumol/L; P = .01), the number of stroke patients evaluated during a typical week (Spearman's r = .32; P = .034), and year of training completion (Spearman's r = .41; P = .003). About half (51%) treat elevated homocysteine with a combination of folate, vitamin B(12), and vitamin B(6). Consistent with observational data, the majority of the neurologists surveyed report that they select young stroke patients who lack traditional stroke risk factors for homocysteine testing. Thresholds for treatment varied between community-based and academic neurologists and correlated with the physicians' stroke patient volume.

Duke Scholars

Published In

J Stroke Cerebrovasc Dis

DOI

EISSN

1532-8511

Publication Date

2005

Volume

14

Issue

3

Start / End Page

101 / 106

Location

United States

Related Subject Headings

  • Neurology & Neurosurgery
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bushnell, C. D., & Goldstein, L. B. (2005). Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients. J Stroke Cerebrovasc Dis, 14(3), 101–106. https://doi.org/10.1016/j.jstrokecerebrovasdis.2005.01.003
Bushnell, Cheryl D., and Larry B. Goldstein. “Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients.J Stroke Cerebrovasc Dis 14, no. 3 (2005): 101–6. https://doi.org/10.1016/j.jstrokecerebrovasdis.2005.01.003.
Bushnell CD, Goldstein LB. Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients. J Stroke Cerebrovasc Dis. 2005;14(3):101–6.
Bushnell, Cheryl D., and Larry B. Goldstein. “Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients.J Stroke Cerebrovasc Dis, vol. 14, no. 3, 2005, pp. 101–06. Pubmed, doi:10.1016/j.jstrokecerebrovasdis.2005.01.003.
Bushnell CD, Goldstein LB. Neurologists' evaluation and treatment of hyperhomocysteinemia in stroke patients. J Stroke Cerebrovasc Dis. 2005;14(3):101–106.
Journal cover image

Published In

J Stroke Cerebrovasc Dis

DOI

EISSN

1532-8511

Publication Date

2005

Volume

14

Issue

3

Start / End Page

101 / 106

Location

United States

Related Subject Headings

  • Neurology & Neurosurgery
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences